KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
19.24
+0.08 (0.42%)
At close: Apr 28, 2026, 4:00 PM EDT
19.56
+0.32 (1.66%)
After-hours: Apr 28, 2026, 5:39 PM EDT
KalVista Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2025 | FY 2024 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Apr '25 Apr 30, 2025 | Dec '24 Dec 31, 2024 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 |
| Revenue | 73.62 | - | - | - | - | |
| Cost of Revenue | 54.68 | 71.71 | 78.25 | 86.17 | 80.28 | |
| Gross Profit | 18.94 | -71.71 | -78.25 | -86.17 | -80.28 | |
| Selling, General & Admin | 185.21 | 116.29 | 97.3 | 54.28 | 30.6 | |
| Operating Expenses | 185.21 | 116.29 | 97.3 | 54.28 | 30.6 | |
| Operating Income | -166.27 | -188 | -175.55 | -140.45 | -110.87 | |
| Interest Expense | -19.34 | -5.79 | - | - | - | |
| Interest & Investment Income | 8.68 | 6.44 | - | 3.9 | 2.23 | |
| Currency Exchange Gain (Loss) | 0.05 | 2.48 | - | 0.14 | 0.09 | |
| Other Non Operating Income (Expenses) | 10.99 | 3.25 | 9.86 | 8.44 | 15.78 | |
| EBT Excluding Unusual Items | -165.89 | -181.61 | -165.68 | -127.97 | -92.77 | |
| Gain (Loss) on Sale of Investments | 1.84 | 1.56 | - | 1.33 | -0.14 | |
| Asset Writedown | -1.79 | - | - | - | - | |
| Pretax Income | -165.84 | -180.05 | -165.68 | -126.64 | -92.91 | |
| Income Tax Expense | -1.55 | 3.39 | - | - | - | |
| Net Income | -164.29 | -183.44 | -165.68 | -126.64 | -92.91 | |
| Net Income to Common | -164.29 | -183.44 | -165.68 | -126.64 | -92.91 | |
| Shares Outstanding (Basic) | 54 | 50 | 48 | 37 | 28 | |
| Shares Outstanding (Diluted) | 54 | 50 | 48 | 37 | 28 | |
| Shares Change (YoY) | 8.49% | 3.53% | 30.37% | 31.89% | 13.96% | |
| EPS (Basic) | -3.05 | -3.69 | -3.45 | -3.44 | -3.33 | |
| EPS (Diluted) | -3.05 | -3.69 | -3.45 | -3.44 | -3.33 | |
| Free Cash Flow | -124.99 | -153.34 | - | -89.27 | -76.46 | |
| Free Cash Flow Per Share | -2.32 | -3.09 | - | -2.43 | -2.74 | |
| Gross Margin | 25.73% | - | - | - | - | |
| Operating Margin | -225.86% | - | - | - | - | |
| Profit Margin | -223.16% | - | - | - | - | |
| Free Cash Flow Margin | -169.79% | - | - | - | - | |
| EBITDA | -164.82 | -187.05 | - | -139.63 | -110.15 | |
| EBITDA Margin | -223.88% | - | - | - | - | |
| D&A For EBITDA | 1.45 | 0.94 | - | 0.82 | 0.72 | |
| EBIT | -166.27 | -188 | -175.55 | -140.45 | -110.87 | |
| EBIT Margin | -225.86% | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.